



## TISSUE THERAPIES

ASX RELEASE

28 January 2009

Dear Option holder

### **2009 Non-renounceable Rights Issue – option holder participation**

Tissue Therapies Limited today lodged its Prospectus, for a non-renounceable rights issue to raise approximately \$3.4 million with ASIC and ASX Limited (**ASX**). A copy of the Prospectus is available on ASX website ([www.asx.com.au](http://www.asx.com.au)) as well as on the Company's website ([www.tissuetherapies.com](http://www.tissuetherapies.com)). The attached letter to shareholders sets out further details of the issue.

Option holders may only participate in the rights issue if the options are exercised prior to the Record Date, being Thursday 10 February 2009.

Please contact our share registry should you wish to exercise your options.

The share registry contact details are:

Postal address:

Link Market Services Limited  
Level 12, 680 George Street  
SYDNEY NSW 2000

Tel: 1300 554 474  
Fax: (02) 3228 4999

Hand delivery:

Link Market Services Limited  
Level 12, 300 Queen Street  
BRISBANE QLD 4000

Yours sincerely

**Steven Mercer**  
Managing Director

## **About Tissue Therapies Limited**

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

**More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)**